{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:14:59Z","timestamp":1777486499254,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7759\/cureus.102627","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:51:21Z","timestamp":1769777481000},"source":"Crossref","is-referenced-by-count":1,"title":["Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss"],"prefix":"10.7759","author":[{"given":"Mira","family":"Sterckx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludo","family":"De Keyser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn W","year":"2024","unstructured":"Ghusn W, Hurtado MD. Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024, 12:100127. 10.1016\/j.obpill.2024.100127","journal-title":"Obes Pillars"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-020-01307-x","article-title":"Euglycemic ketoacidosis","volume":"20","author":"Bonora BM","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020, 20:25. 10.1007\/s11892-020-01307-x","journal-title":"Curr Diab Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.33","article-title":"Metabolic acidosis: pathophysiology, diagnosis and management","volume":"6","author":"Kraut JA","year":"2010","unstructured":"Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010, 6:274-85. 10.1038\/nrneph.2010.33","journal-title":"Nat Rev Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01749-x","article-title":"GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: a brief review","volume":"49","author":"Sood N","year":"2025","unstructured":"Sood N, Buddhavarapu V, Garg R. GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: a brief review. Int J Obes (Lond). 2025, 49:977-9. 10.1038\/s41366-025-01749-x","journal-title":"Int J Obes (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1410","article-title":"Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline","volume":"94","author":"Cryer PE","year":"2009","unstructured":"Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009, 94:709-28. 10.1210\/jc.2008-1410","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae156","article-title":"Euglycemic ketoacidosis from semaglutide in a patient without diabetes","volume":"2","author":"Sood N","year":"2024","unstructured":"Sood N, Bansal O, Garg R, Hoskote A. Euglycemic ketoacidosis from semaglutide in a patient without diabetes. JCEM Case Rep. 2024, 2:luae156. 10.1210\/jcemcr\/luae156","journal-title":"JCEM Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83187","article-title":"Euglycemic ketoacidosis in a non-diabetic patient after tirzepatide use: a cautionary tale","volume":"17","author":"Singh R","year":"2025","unstructured":"Singh R. Euglycemic ketoacidosis in a non-diabetic patient after tirzepatide use: a cautionary tale. Cureus. 2025, 17:e83187. 10.7759\/cureus.83187","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2022.76.221-223","article-title":"A liraglutide injection superimposing a starvation acidosis: a case report","volume":"76","author":"Alghamdi M","year":"2022","unstructured":"Alghamdi M, Almulhim M, Alkhadra F, Alahmadi S, Alzahid A, Al-Mulhim A. A liraglutide injection superimposing a starvation acidosis: a case report. Med Arch. 2022, 76:221-3. 10.5455\/medarh.2022.76.221-223","journal-title":"Med Arch"},{"key":"ref11","unstructured":"European Medicines Agency. Warning about sharp rise in illegal medicines sold in the EU. (2025). Accessed: January 26, 2026: https:\/\/www.ema.europa.eu\/en\/news\/warning-about-sharp-rise-illegal-medicines-sold-eu."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28280","article-title":"Safety and risk assessment of no-prescription online semaglutide purchases","volume":"7","author":"Ashraf AR","year":"2024","unstructured":"Ashraf AR, Mackey TK, Schmidt J, Kulcs\u00e1r G, Vida RG, Li J, Fittler A. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open. 2024, 7:e2428280. 10.1001\/jamanetworkopen.2024.28280","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452643-euglycemic-ketoacidosis-following-the-use-of-counterfeit-semaglutide-for-weight-loss","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:51:22Z","timestamp":1769777482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452643-euglycemic-ketoacidosis-following-the-use-of-counterfeit-semaglutide-for-weight-loss"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.102627","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}